AMSBIO announces a Custom Chimeric Antigen Receptor T cell (CAR-T) service designed to take advantage of the astonishing clinical breakthroughs achieved with CAR-T cells in various hematological malignancies.CAR-T cell therapy is a groundbreaking immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatible complex molecules. The CAR-T cell therapies have been widely used in the treatment of…
Cambridge, UK, 28 January 2020 Mogrify Ltd (Mogrify™), a UK company aiming to transform the development of cell therapies, today announced that it has secured $1.1M of additional funding from SBRI Healthcare, the NHS England funded initiative championed by the Academic Health Science Network (AHSN), to assess its regenerative cartilage therapy, for the treatment of cartilage defects, osteoarthritis and other musculoskeletal conditions, before entering clinical trials. This grant follows on from the Phase I funding announced earlier this year, which enabled Mogrify to identify the…
Westbury, NY – Jan. 27, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has been selected by upcyte® technologies GmbH as the exclusive commercial worldwide distributor of its cell products and media, including cells derived from hepatocytes and liver sinusoidal endothelial cells (LSECs).
“We are pleased to be able to provide our clients with upcyte hepatic cells, which can be used for predictive toxicology evaluations and screening studies, and nicely complement our portfolio of primary hepatocytes and other…
Sandwich, Kent, UK, January 22 2020 – Over 200 local school pupils have taken part in unique hands-on scientific learning opportunities at Discovery Park since the relaunch of its Community Lab last year. As is clear from the Community Lab January 2020 Impact Report, published today, students and teachers alike have been inspired by the activities, established to encourage children to adopt scientific careers and grow the local STEM1 skills base. The Community Lab at Discovery Park, the thriving science park for ambitious and growing life sciences companies, is a unique collaboration between…
Cambridge, UK, 21 January 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that it will license its gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line to NGM Biopharmaceuticals, Inc. (“NGM”) (Nasdaq: NGM). A clinical stage biopharmaceutical company based in South San Francisco, California, NGM is focused on developing novel therapeutics based on scientific understanding of key biological pathways…
Cambridge, UK, 21 January: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed that it has entered into a commercial agreement with CCL, to provide PredictSURE IBD™ to clinicians and gastroenterologists in the UK, Ireland (non-exclusive), the Middle East and the Balkans (exclusively).
Under the agreement, Cambridge based CCL will manage and facilitate the fulfilment of orders of PredictSURE IBD™, as well as receive and process all samples.…
Cambridge, UK, 21 January 2020: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project collaboration with Otsuka Pharmaceutical Co., the world-leading pharmaceutical company dedicated to the research and development of highly-innovative drugs and diagnostics. Financial details of the agreement are not disclosed.
PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, towards disease relevant pathways nominated by Otsuka. Novel targets…
Cambridge, UK., 16 January 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces Dr Jan Jezek, Chief Scientific Officer, will present at PEPTalk 2020, in San Diego, California, USA on 20-24 January 2020.
Dr. Jezek’s PEPTalk presentation, entitled ‘Controlling Aggregation of a Range of Novel Biopharmaceutical Product Modalities’, will summarise several case studies demonstrating the capability of Arecor’s formulation technology platform, Arestat™, to develop differentiated biopharmaceutical…
Cambridge, UK, 14 January 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation technologies, today announced that it will provide access to a novel base editing technology licensed from Rutgers, The State University of New Jersey, for exclusive use in therapeutic, diagnostic and services applications. This technology is incorporated into Horizon’s next-generation gene editing platform to enable the development of novel therapeutics that rely on engineering patient’s cells either directly…